Condition: Acute Myeloid Leukemia, in Relapse · Myelodysplastic Syndromes · Chronic Myeloid Leukemia · Sponsor: St. Petersburg State Pavlov Medical University
This is a single-center randomized open-label phase II clinical trial to compare relapse prophylaxis with sorafenib and observation after graft-versus-host disease prophylaxis with post-transplantation bendamustine and cyclophosphamide in high-risk myeloid malignancies. This is an intention to treat study, where randomization is performed at first documentation of CR after engraftment.
This description comes directly from the study's public registry record.
IVAN S MOISEEV · +78123386265 · moisiv@mail.ru
Irina V Bykova · +78123386617 · bmt-director@1spbgmu.ru
Always discuss trial participation with your own doctor first.
| RM Gorbacheva Research Institute | Saint Petersburg, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06532084